Journal
ONCOTARGET
Volume 8, Issue 48, Pages 84559-84571Publisher
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.19187
Keywords
drug resistance; MDR; prevention; Pgp; Pgp inhibitor
Categories
Funding
- National Natural Science Foundation of China [81402266, 81372875]
- Gattegno fund
- Wechsler fund
- China Scholarship Council
- Joint Research Fund devoted to clinical pharmacy and precision medicine
Ask authors/readers for more resources
The development of multidrug resistance (MDR) is one of the major challenges to the success of traditional chemotherapy treatment in cancer patients. Most studies to date have focused on strategies to reverse MDR following its development. However, agents utilizing this approach have proven to be of limited clinical use, failing to demonstrate an improvement in therapeutic efficacy with almost no significant survival benefits observed in cancer clinical trials. An alternative approach that has been applied is to prevent or delay MDR prior or early in its development. Recent investigations have shown that preventing the emergence of MDR at the onset of chemotherapy treatment, rather than reversing MDR once it has developed, may assist in overcoming drug resistance. In this review, we focus on a number of novel strategies used by small-molecule inhibitors to prevent the development of MDR. These agents hold great promise for prolonging the efficacy of chemotherapy treatment and improving the clinical outcomes of patients with cancers that are susceptible to MDR development.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available